Maat Pharma SA

Research Maat Pharma SA (MAAT) on Bullrun: market cap EUR 47.67M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMAAT
• ExchangePA
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 47.67M
• Financial periodFY2024
• RevenueEUR 3.22M
• Revenue growth44.3%
• Net income-EUR 28.90M
• Free cash flow-EUR 22.79M
• Gross margin61.1%

Valuation Snapshot

latest market cap is EUR 47.67M.

About Maat Pharma SA

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation;

Frequently asked questions

What is Maat Pharma SA's market cap?

Maat Pharma SA's market capitalization is EUR 47.67M.

What does Maat Pharma SA do?

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.